Personalized immunotherapy for the treatment of non-Hodgkin lymphoma

A promising approach

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The efficacy of immunotherapeutic strategies for the treatment of lymphoid malignancies has been demonstrated in recent years. In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome. Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies. This therapeutic modality appears safe, with the most common adverse events being transient, local reactions at the site of injection. Furthermore, personalized immunotherapy has the potential to generate immunologic memory, which could provide prolonged remission. Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma. It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma.

Original languageEnglish (US)
Pages (from-to)923-932
Number of pages10
JournalClinical Advances in Hematology and Oncology
Volume3
Issue number12
StatePublished - Dec 1 2005

Fingerprint

Non-Hodgkin's Lymphoma
Immunotherapy
Lymphoma
Immunologic Memory
Follicular Lymphoma
Passive Immunization
B-Cell Lymphoma
Hematologic Neoplasms
Therapeutics
Immune System
Neoplasms
Monoclonal Antibodies
Clinical Trials
Safety
Injections

Keywords

  • Idiotype
  • Immunotherapy
  • Lymphoma
  • Vaccine

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Personalized immunotherapy for the treatment of non-Hodgkin lymphoma : A promising approach. / Vose, Julie Marie.

In: Clinical Advances in Hematology and Oncology, Vol. 3, No. 12, 01.12.2005, p. 923-932.

Research output: Contribution to journalArticle

@article{e69ba866dae449b4a8152e52e0c78d2c,
title = "Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: A promising approach",
abstract = "The efficacy of immunotherapeutic strategies for the treatment of lymphoid malignancies has been demonstrated in recent years. In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome. Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies. This therapeutic modality appears safe, with the most common adverse events being transient, local reactions at the site of injection. Furthermore, personalized immunotherapy has the potential to generate immunologic memory, which could provide prolonged remission. Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma. It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma.",
keywords = "Idiotype, Immunotherapy, Lymphoma, Vaccine",
author = "Vose, {Julie Marie}",
year = "2005",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "923--932",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "12",

}

TY - JOUR

T1 - Personalized immunotherapy for the treatment of non-Hodgkin lymphoma

T2 - A promising approach

AU - Vose, Julie Marie

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The efficacy of immunotherapeutic strategies for the treatment of lymphoid malignancies has been demonstrated in recent years. In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome. Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies. This therapeutic modality appears safe, with the most common adverse events being transient, local reactions at the site of injection. Furthermore, personalized immunotherapy has the potential to generate immunologic memory, which could provide prolonged remission. Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma. It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma.

AB - The efficacy of immunotherapeutic strategies for the treatment of lymphoid malignancies has been demonstrated in recent years. In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome. Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies. This therapeutic modality appears safe, with the most common adverse events being transient, local reactions at the site of injection. Furthermore, personalized immunotherapy has the potential to generate immunologic memory, which could provide prolonged remission. Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma. It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma.

KW - Idiotype

KW - Immunotherapy

KW - Lymphoma

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=31644438890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31644438890&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 923

EP - 932

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 12

ER -